Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Runtong Syrup
- Development stage
- Unknown
- Lead developer
- Suzhou Yusen New Drug Development
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Xiaoer Runtong Syrup is a traditional Chinese medicine (TCM) Class 1.1 innovative drug developed by Suzhou Yusen New Drug Development and Hainan Huluwa Pharmaceutical Group. Formulated as an oral syrup, it is designed for the treatment of pediatric constipation, specifically targeting food accumulation syndrome (食积证). The drug received clinical trial clearance (IND approval) from China's National Medical Products Administration (NMPA) in March 2026.
- Other names
- 小儿润通糖浆
Beyond the preview
Go deeper on Xiaoer Runtong Syrup.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiaoer Runtong Syrup.